VG Life Sciences Inc. (VGLS)

[palmspringsbum]

From the Research 2.0 report (IV means Intrinsic Value):

Although it has great potential, we are leaving VG Energy out of our IV methodology and treating it as a free out-of-the-money call option.

Our base case IV model values Viral’s shares at $0.47.

It assumes the company is successful in Phase 1 and 2 clinical trials with its HIV and drug-resistant cancer therapies, and is further able to strike licensing deals with established biopharmaceutical companies to complete clinical testing and take on the market within the next 3-5 years.

Also coming soon:

With the successful conclusion of the lawsuit, we expect Viral to return to full reporting and list on the OTCBB.

Also in the coming months, a separate report on VG Energy.